Fig. 2.

Efficacy of CHM compared with α2-adrenergic agonists (A), and opioid agonists (B) in relieving anxiety. Summary estimates of the weighted mean differences (WMDs) and their 95% CIs are given at three time points. “Beginning” and “End” in (A) and “Beginning,” “middle,” and “End” in (B) were analyzed in fixed-effects models. The other time points were analyzed in random-effects models. N_R indicates the fail-safe number, i.e. the number of unpublished negative studies that would be required to overturn each significant finding at an alpha level of 0.05